Advanced search

71 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth	03-21	AQ
Bayer - Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer's elinzanetant	03-20	AQ
Bayer plans to apply for approval of drug to treat menopausal symptoms	03-19	DP
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	03-13	AQ
Bayer AG - BlueRock Therapeutics phase I clinical trial for Parkinson's disease continues to show positive trends at 18 months	03-07	AQ
Bayer : BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months	03-06	PU
Transcript : Bayer Aktiengesellschaft - Analyst/Investor Day	03-05
Transcript : Bayer Aktiengesellschaft, 2023 Earnings Call, Mar 05, 2024	03-05
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis	02-21	AQ
Bayer AG - First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure	02-14	AQ
Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor	02-07	AQ
Transcript : Bayer Aktiengesellschaft Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 11:15 AM	01-09
Bayer starts Phase II study NIRVANA to evaluate elinzanetant in women with sleep disturbances associated with menopause	01-09	AQ
Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies	01-09	AQ
Transcript : Bayer Aktiengesellschaft - Special Call	11-21
Bayer - OCEANIC-AF study stopped early due to lack of efficacy	11-20	AQ
Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy	11-20	DJ
Bayer : aflibercept 8 mg recommended for approval in EU	11-10	PU
Bayer - New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment	11-07	AQ
Bayer : New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment	11-06	PU
Bayer : Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator	18/09/23	PU
Bayer : BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint	28/08/23	PU
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial	28/08/23	RE
Transcript : Bayer Aktiengesellschaft, Q2 2023 Earnings Call, Aug 08, 2023	08/08/23
Bayer - BlueRock's neuronal stem cell therapy for Parkinson's disease is first to show positive results in Phase I clinical study	29/06/23	AQ
Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations	29/06/23	AQ
Transcript : Bayer Aktiengesellschaft - Special Call	27/06/23
Bayer : receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program	16/05/23	PU
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology	10/05/23	BU
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology	10/05/23	BU
Bayer : submits aflibercept 8 mg for marketing authorization in Japan	01/03/23	PU
Bayer : submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU	06/02/23	PU
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros	11/01/23	AQ
Bayer Raises Combined Peak Sales Forecast for Pharma Portfolio	10/01/23	DJ
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes	19/12/22	AQ
Bayer : Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes	16/12/22	PU
Bayer : receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity	11/11/22	PU
Bayer AG - Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16	07/11/22	AQ
Bayer : Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16	05/11/22	PU
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy	18/10/22	AQ
Bayer AG - Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients	09/09/22	AQ
Bayer : opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology	29/06/22	PU
Bayer : delivers on medical innovation fueling transformation of pharma business	21/02/22	PU
Transcript : Bayer Aktiengesellschaft - Special Call	18/02/22
EU Drug Regulator Recommends Bayer Kidney Treatment for Marketing Authorization	17/12/21	DJ
Transcript : Bayer Aktiengesellschaft - Special Call	15/11/21
Transcript : Bayer Aktiengesellschaft Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-11-2021 08:00 AM	11/11/21
Transcript : Bayer Aktiengesellschaft, Q3 2021 Earnings Call, Nov 09, 2021	09/11/21
Change in Directors and/or Officers (Resignation, Removal or Appointment, Election and/or Promotion)	01/11/21	PU
Bayer : Extends Clinical Development Program for KERENDIA® (finerenone) With Phase III Study to Investigate Use in Patients With Nondiabetic Chronic Kidney Disease	20/09/21	BU

No results for this search

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer